DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $49,024,237 | +2.4% | 197,599 | -0.9% | 0.09% | +6.0% |
| Q2 2023 | $47,854,069 | -6.2% | 199,392 | -1.5% | 0.08% | -13.4% |
| Q1 2023 | $51,008,067 | +0.7% | 202,381 | +6.0% | 0.10% | -4.9% |
| Q4 2022 | $50,667,082 | -12.0% | 190,882 | -14.4% | 0.10% | -20.3% |
| Q3 2022 | $57,582,000 | +4.1% | 222,926 | +2.1% | 0.13% | +6.7% |
| Q2 2022 | $55,333,000 | -13.1% | 218,246 | +0.6% | 0.12% | 0.0% |
| Q1 2022 | $63,662,000 | -17.5% | 217,017 | -7.4% | 0.12% | -16.7% |
| Q4 2021 | $77,128,000 | +6.0% | 234,420 | -1.9% | 0.14% | -2.0% |
| Q3 2021 | $72,752,000 | +7.1% | 238,961 | -5.6% | 0.15% | +5.8% |
| Q2 2021 | $67,947,000 | +18.0% | 253,184 | -1.1% | 0.14% | +6.9% |
| Q1 2021 | $57,605,000 | +5.5% | 255,918 | +4.2% | 0.13% | -4.4% |
| Q4 2020 | $54,585,000 | +0.6% | 245,709 | -2.4% | 0.14% | -12.3% |
| Q3 2020 | $54,237,000 | +42.2% | 251,870 | +16.8% | 0.16% | +28.1% |
| Q2 2020 | $38,138,000 | +31.1% | 215,656 | +2.6% | 0.12% | -4.7% |
| Q1 2020 | $29,091,000 | -4.2% | 210,150 | +6.3% | 0.13% | +30.9% |
| Q4 2019 | $30,358,000 | -1.7% | 197,776 | -7.5% | 0.10% | -13.4% |
| Q3 2019 | $30,897,000 | +11.0% | 213,913 | +9.8% | 0.11% | +4.7% |
| Q2 2019 | $27,847,000 | +9.2% | 194,817 | +0.9% | 0.11% | +0.9% |
| Q1 2019 | $25,494,000 | +62.3% | 193,093 | +26.7% | 0.11% | +27.7% |
| Q4 2018 | $15,712,000 | +10.0% | 152,361 | +15.9% | 0.08% | +27.7% |
| Q3 2018 | $14,283,000 | +23.6% | 131,442 | +12.3% | 0.06% | +10.2% |
| Q2 2018 | $11,554,000 | +26.5% | 117,084 | +25.5% | 0.06% | +13.5% |
| Q1 2018 | $9,137,000 | +34.4% | 93,324 | +27.4% | 0.05% | +20.9% |
| Q4 2017 | $6,800,000 | +12.4% | 73,261 | +3.9% | 0.04% | +10.3% |
| Q3 2017 | $6,051,000 | +3.4% | 70,541 | +1.7% | 0.04% | -2.5% |
| Q2 2017 | $5,852,000 | +1.0% | 69,348 | +2.4% | 0.04% | -9.1% |
| Q1 2017 | $5,794,000 | -14.1% | 67,744 | -21.9% | 0.04% | -22.8% |
| Q4 2016 | $6,748,000 | -14.3% | 86,689 | -23.6% | 0.06% | -18.6% |
| Q3 2016 | $7,871,000 | -15.6% | 113,396 | +7.3% | 0.07% | -22.2% |
| Q2 2016 | $9,329,000 | +31.7% | 105,709 | +19.4% | 0.09% | +9.8% |
| Q1 2016 | $7,086,000 | +3.4% | 88,548 | +20.0% | 0.08% | +2.5% |
| Q4 2015 | $6,855,000 | +12.4% | 73,807 | +3.1% | 0.08% | -21.6% |
| Q3 2015 | $6,097,000 | +173.2% | 71,554 | +174.4% | 0.10% | -35.8% |
| Q2 2015 | $2,232,000 | +9.7% | 26,074 | -18.8% | 0.16% | +169.5% |
| Q2 2013 | $2,034,000 | – | 32,127 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |